Aude Fléchon

25.1k total citations · 3 hit papers
273 papers, 7.7k citations indexed

About

Aude Fléchon is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Aude Fléchon has authored 273 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Surgery, 139 papers in Pulmonary and Respiratory Medicine and 113 papers in Oncology. Recurrent topics in Aude Fléchon's work include Testicular diseases and treatments (75 papers), Bladder and Urothelial Cancer Treatments (75 papers) and Prostate Cancer Treatment and Research (65 papers). Aude Fléchon is often cited by papers focused on Testicular diseases and treatments (75 papers), Bladder and Urothelial Cancer Treatments (75 papers) and Prostate Cancer Treatment and Research (65 papers). Aude Fléchon collaborates with scholars based in France, United States and United Kingdom. Aude Fléchon's co-authors include Karim Fizazi, Cora N. Sternberg, Fred Saad, Johann S. de Bono, Kurt Miller, Kim N., Neal D. Shore, Ronald de Wit, Paul N. Mainwaring and Thomas W. Flaig and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Aude Fléchon

257 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

2012 3.3k citations Karim Fizazi, Cora N. Sternberg et al. profile →
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology profile →
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

2018 281 citations Robert H. Jones, Aude Fléchon et al. profile →

Peers

Countries citing papers authored by Aude Fléchon

Since Specialization

Citations

This map shows the geographic impact of Aude Fléchon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aude Fléchon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aude Fléchon more than expected).

Fields of papers citing papers by Aude Fléchon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aude Fléchon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aude Fléchon. The network helps show where Aude Fléchon may publish in the future.

Co-authorship network of co-authors of Aude Fléchon

This figure shows the co-authorship network connecting the top 25 collaborators of Aude Fléchon. A scholar is included among the top collaborators of Aude Fléchon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aude Fléchon. Aude Fléchon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients 2025 ·BJUI Compass ·(unknown), Aude Fléchon, G. Pignot, (unknown), J. Rigaud, M. Roumiguié, (unknown), Constance Thibault, Laurence Crouzet, (unknown), (unknown), Marine Gross‐Goupil, Luca Campedel, Mathieu Laramas, Thomas Filleron, E. Martin, Léonor Chaltiel, Damien Pouessel	0
2	Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin 2025 ·European Journal of Cancer ·(unknown), (unknown), Sylvie Chabaud, (unknown), (unknown), Aude Fléchon, Helen Boyle, Armelle Vinceneux, F. Bérard, Benoît You, Gilles Freyer, (unknown), Sophie Tartas, Mona Amini‐Adlé	1
3	Impact of a one-year supervised physical activity program on long-term cancer-related fatigue and mediating effects of the gut microbiota in metastatic testicular cancer patients: protocol of the prospective multicentre, randomized controlled phase-III STARTER trial 2024 ·BMC Cancer ·Hwayoung Noh, Amélie Anota, (unknown), (unknown), (unknown), Camille Schiffler, (unknown), Sabina Rinaldi, Joël Lachuer, Pekka Keski‐Rahkonen, Marc J. Gunter, Aude Fléchon, Béatrice Fervers, Olivia Pérol	2
4	Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial 2024 ·Journal of Clinical Oncology ·Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon, Lance C. Pagliaro, J. Mardiak, Lionnel Geoffrois, Brigitte Laguerre, Christine Chevreau, R. Delva, Frédéric Rolland, Christine Théodore, Guilhem Roubaud, Gwénaëlle Gravis, Jean-Christophe Eymard, Mathilde Cancel, Béata Juzyna, Mária Rečková, (unknown), C. Logothetis, Stéphane Culine	4
5	A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer 2024 ·Future Oncology ·Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip L. Palmbos, Arjun Vasant Balar, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, (unknown), (unknown), Petros Grivas, Philippe Barthélémy, Rick Bangs, Scott T. Tagawa	1
6	Primary urethral carcinoma: Recommendations of the oncology committee of the French Urology Association 2024 ·PubMed ·P. Neuville, T. Murez, (unknown), L. Rocher, Aude Fléchon, L. Ferretti, (unknown), Nicolas Branger, Philippe Camparo, Morgan Rouprêt	2
7	French AFU Cancer Committee Guidelines – Update 2024–2026 : Assessment of an adrenal incidentaloma and oncological management 2024 ·PubMed ·P.-H. Savoie, T. Murez, L. Rocher, P. Neuville, (unknown), Aude Fléchon, Nicolas Branger, Philippe Camparo, Morgan Rouprêt	2
8	A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 2024 ·Clinical Cancer Research ·Neeraj Agarwal, Daniel Castellano, Teresa Alonso‐Gordoa, Jóse Ángel Arranz Arija, Émeline Colomba, Gwénaëlle Gravis, Loı̈c Mourey, Stéphane Oudard, Aude Fléchon, (unknown), Pablo Maroto, Michael T. Schweizer, Enrique Gallardo, (unknown), Arjun Vasant Balar, Nadine Haddad, Adams K. Appiah, (unknown), Josep M. Piulats	6
9	Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study 2024 ·Clinical Genitourinary Cancer ·Thomas Powles, Tibor Csőszi, Yohann Loriot, Nobuaki Matsubara, Lajos Géczi, Susanna Cheng, Yves Fradet, Ajjai Alva, Stéphane Oudard, Christof Vulsteke, Rafael Morales‐Barrera, Aude Fléchon, Şeyda Gündüz, Chih‐Chin Liu, Blanca Homet Moreno, Abhishek Bavle, Mustafa Özgüroğlu	0
10	Bone Metastases in Non-Seminomatous Germ Cell Tumors: A 20-Year Retrospective Analysis 2024 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), Patrice Peyrat, Helen Boyle, Aude Fléchon	1
11	1814P First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France 2023 ·Annals of Oncology ·(unknown), Patrick Olivier, (unknown), Aude Fléchon, (unknown), (unknown), (unknown), Philippe Barthélémy, (unknown), (unknown), Yann Godbert, Guilhem Roubaud	1
12	Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial 2023 ·Cancers ·Stéphane Culine, Valentin Harter, Clémentine Krucker, Gwénaëlle Gravis, Aude Fléchon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Jacqueline Fontugne, Yves Allory, Christian Pfister	6
13	Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer 2023 ·NEJM Evidence ·Karim Fizazi, Alice Bernard‐Tessier, Guilhem Roubaud, Tapio Utriainen, Philippe Barthélémy, Aude Fléchon, (unknown), Gwénaëlle Gravis, Raffaele Ratta, Robert H. Jones, Omi Parikh, Minna Tanner, Emmanuel S. Antonarakis, Capucine Baldini, (unknown), Chris Garratt, Tarja Ikonen, Pasi Pohjanjousi, Heikki Joensuu, Natalie Cook	13
14	2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM) 2023 ·Annals of Oncology ·Philippe Barthélémy, Yohann Loriot, Aude Fléchon, M. Gross Goupil, Éric Voog, (unknown), Véronique Lorgis, Damien Pouessel, (unknown), Christophe Sajous, (unknown), Aline Guillot, (unknown), Éric Amela, Constant Josse, (unknown), (unknown), Constance Thibault	2
15	Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma 2023 ·Pharmaceuticals ·Anne‐Laure Giraudet, Armelle Vinceneux, (unknown), (unknown), (unknown), (unknown), Jean‐Noël Badel, Helen Boyle, Aude Fléchon, David Kryza	6
16	French AFU Cancer Committee Guidelines Update 2022–2024: Adrenal tumor – Assessment of an adrenal incidetaloma and oncological management 2022 ·Progrès en Urologie ·P.-H. Savoie, T. Murez, P. Neuville, (unknown), L. Rocher, Aude Fléchon, Philippe Camparo, L. Ferretti, Nicolas Branger, Morgan Rouprêt	3
17	French AFU Cancer Committee Guidelines - Update 2022-2024: penile cancer 2022 ·Progrès en Urologie ·P.-H. Savoie, T. Murez, P. Neuville, L. Ferretti, L. Rocher, (unknown), Philippe Camparo, Aude Fléchon, Nicolas Branger, Morgan Rouprêt	4
18	Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma 2021 ·European Journal of Cancer ·Lucía Carril-Ajuria, Émeline Colomba, Luigi Cerbone, Carmen Romero, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cécile Vicier, Guillermo de Velasco, Aude Fléchon, (unknown), Patrick R. Benusiglio, Brigitte Bressac–de Paillerets, Marine Guillaud-Bataille, Pauline Gaignard, Jean‐Yves Scoazec, Richard J. Kahnoski, Olivier Caron, Bernard Escudier, Laurence Albigès	24
19	Brain metastases from germ cell tumor: time to reconsider radiotherapy? 2020 ·Critical Reviews in Oncology/Hematology ·Jonathan Khalifa, Aude Fléchon, Christine Chevreau	5
20	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study 2017 ·Clinical Cancer Research ·(unknown), Christine Chevreau, Sophie Broutin, Jérôme Guitton, Bénédicte Lelièvre, Joseph Ciccolini, (unknown), Aude Fléchon, R. Delva, Gwénaëlle Gravis, Jean‐Pierre Lotz, Jacques‐Olivier Bay, Marine Gross‐Goupil, Angélo Paci, (unknown), (unknown), Étienne Chatelut, Fabienne Thomas	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact